Explain this page
Arphra AIPlain-English read on Thermo Fisher Scientific Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.31% | +7.11% | +5.29% | -2.86% | -14.87% | -14.74% | +24.61% | -5.02% | +9.98% | +221.75% | +39109.52% |
Aftermarket
LiveLast trade
$491.94
406 sh
Bid
$485.00
40 sh
Ask
$493.50
1 sh
Spread
$8.500
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Medical - Diagnostics & Research+0.51%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
$490.75
-0.67% vs spot
Recommendation
Hold
18 of 19 methods
Method spread
4bull13bear
±5% threshold
Analyst PT consensus: $654.67 (+32.51%)
Total assets
$110.34B
Total debt
$40.86B
Cash & equiv
$9.86B
Operating CF
$7.82B
Free cash flow
$6.29B
Buybacks
-$3B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$654.67
+32.51% upside
Low
$600.00
Median
$650.00
High
$750.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Nalgene Outdoor Introduces Fresh Flow™ Straw Bottlebusinesswire.com·May 11, 2026
- Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trialsbusinesswire.com·May 06, 2026
- International Markets and Thermo Fisher (TMO): A Deep Dive for Investorszacks.com·May 04, 2026
- Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturingbusinesswire.com·May 04, 2026
- Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturingbusinesswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $11.01B | $1.65B | $4.43 |
| Q4 Dec 2025 | $12.22B | $1.98B | $5.21 |
| Q3 Sep 2025 | $11.12B | $1.62B | $4.27 |
| Q2 Jun 2025 | $10.86B | $1.62B | $4.28 |
| Q1 Mar 2025 | $10.36B | $1.51B | $3.98 |
| Q4 Dec 2024 | $11.4B | $1.83B | $4.78 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Pettiti Gianluca officer: President & COO | Sell | 400 | $185.06K | Apr 27, 2026 |
Shafer Michael D officer: Executive Vice President | Sell | 1,607 | $802.54K | Mar 11, 2026 |
CASPER MARC N director, officer: Chairman & CEO | Sell | 348 | $179.44K | Mar 05, 2026 |
CASPER MARC N director, officer: Chairman & CEO | Sell | 201 | $103.86K | Mar 05, 2026 |
CASPER MARC N director, officer: Chairman & CEO | Sell | 20 | $10.07K | Mar 05, 2026 |
CASPER MARC N director, officer: Chairman & CEO | Sell | 264 | $137.21K | Mar 05, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $44.56B | $8.11B | $6.74B | $17.74 | +15.12% |
| FY 2024 | $42.88B | $7.66B | $6.34B | $16.53 | +14.77% |
| FY 2023 | $42.86B | $7.45B | $6B | $15.45 | +13.99% |
| FY 2022 | $44.92B | $8.53B | $6.95B | $17.64 | +15.47% |
| FY 2021 | $39.21B | $10.32B | $7.73B | $19.46 | +19.70% |